Table 3.

PSA decline values at pre-specified time points.

	25th week (n = 50)	1 month after enzalutamide (n = 51)	3 months after enzalutamide (n = 51)	6 months after enzalutamide (n = 51)
PSA decline ≥80%	50/50 (100%)(95% CI: 92.89–100%)	51/51 (100%)(95% CI: 93.02–100%)	51/51 (100%)(95% CI: 93.02–100%)	51/51 (100%)(95% CI: 93.02–100)
PSA decline ≥90%	50/50 (100%)(95% CI: 92.89–100%)	51/51 (100%)(95% CI: 93.02–100%)	46/51 (90.2%)(95% CI: 78.59–96.74%)	45/51 (88,24%)(95% CI: 76.13–95.56%)
PSA <0.2 ng/ml	50/50 (100%)(95% CI: 92.89–100%)	42/51 (82.3%)(95% CI: 69.13–91.6%)	29/51 (56.8%)(95% CI: 42.25–70.65%)	26/51 (50.98%)(95% CI: 36.6–65.25%)
PSA <0.1 ng/ml	44/50 (88%)(95% CI: 75.69–95.47%)	37/51 (72.5%)(95% CI: 58.26–84.11%)	13/51 (25.5%)(95% CI: 14.33–39.63)	9/51 (17.6%)(95% CI: 8.4–30.87%)